name: tooluniverse-clinical-risk-scoring
description: Compute and interpret validated bedside clinical risk scores and pretest probabilities for an INDIVIDUAL patient — pick the right score for the scenario, gather inputs, run the deterministic calculator tool, and read the result against an interpretation table. Covers CHA2DS2-VASc (AF stroke risk), HAS-BLED (bleeding on anticoagulation), CURB-65 (pneumonia severity / admit decision), qSOFA (sepsis screen), Child-Pugh + MELD-Na (cirrhosis severity / transplant priority), Wells DVT and Wells PE (VTE pretest probability), ASCVD (10-year cardiovascular risk / statin decision), and eGFR CKD-EPI (kidney function / drug dosing). Use when asked things like "stroke risk for this AF patient", "should this patient be anticoagulated", "pneumonia severity — admit or not?", "sepsis screen this patient", "DVT/PE pretest probability", "10-year cardiovascular risk", "cirrhosis severity / MELD score", or "eGFR / kidney function". Pairs CHA2DS2-VASc with HAS-BLED to weigh anticoagulation. NOT for polygenic/genetic risk (use tooluniverse-polygenic-risk-score), NOT for population-level epidemiology/incidence (use tooluniverse-epidemiological-analysis), and NOT for diagnostic test sensitivity/specificity/likelihood-ratio math (use tooluniverse-diagnostic-test-evaluation).
disable-model-invocation: true
Clinical Risk Scoring
Turn a clinical scenario into the right validated risk score, compute it with a deterministic calculator tool, and interpret the number into a clinical action. All 10 backing tools are pure-compute (no network, no API key) and return {status, data:{score, interpretation, components, ...}}.
This skill is decision-support only — see LIMITATIONS. It does not replace clinical judgment.
Step 1 — Map the scenario to the score(s)
| Clinical scenario |
Score(s) |
Tool(s) |
| Atrial fibrillation — stroke risk / anticoagulate? |
CHA2DS2-VASc and HAS-BLED (pair) |
ClinicalCalc_CHA2DS2_VASc + ClinicalCalc_HAS_BLED |
| Community-acquired pneumonia — severity / admit? |
CURB-65 |
ClinicalCalc_CURB_65 |
| Suspected sepsis (infection + ? deterioration) |
qSOFA |
ClinicalCalc_qSOFA |
| Cirrhosis / chronic liver disease severity |
Child-Pugh and MELD-Na (pair) |
ClinicalCalc_Child_Pugh + ClinicalCalc_MELD_Na |
| Suspected DVT — pretest probability |
Wells DVT |
ClinicalCalc_Wells_DVT |
| Suspected PE — pretest probability |
Wells PE |
ClinicalCalc_Wells_PE |
| Primary CVD prevention — 10-yr risk / statin? |
ASCVD |
ClinicalCalc_ASCVD_risk |
| Kidney function / renal drug dosing / CKD stage |
eGFR CKD-EPI |
ClinicalCalc_eGFR_CKD_EPI |
When the scenario names a pair, always run both — one alone is misleading (e.g. stroke risk without bleeding risk, or Child-Pugh without MELD-Na).
Step 2 — Gather the required inputs
Required vs optional inputs per tool (omitted booleans default to false/absent; omitted scalars are rejected when required):
| Tool |
Required |
Key optional booleans/values |
ClinicalCalc_CHA2DS2_VASc |
age |
chf, hypertension, diabetes, stroke_history(2pt), vascular_disease, female |
ClinicalCalc_HAS_BLED |
age |
hypertension, renal_disease, liver_disease, stroke_history, bleeding_history, labile_inr, drugs, alcohol |
ClinicalCalc_CURB_65 |
age |
confusion, elevated_urea(BUN>19), high_resp_rate(>=30), low_bp |
ClinicalCalc_qSOFA |
(none) |
high_resp_rate(>=22), altered_mentation, low_sbp(<=100) |
ClinicalCalc_Child_Pugh |
bilirubin, albumin, inr |
ascites(none/mild/moderate), encephalopathy(none/grade1-2/grade3-4) |
ClinicalCalc_MELD_Na |
creatinine, bilirubin, inr, sodium |
dialysis (forces creatinine to 4.0) |
ClinicalCalc_Wells_DVT |
(none) |
active_cancer, immobilization, recent_surgery, localized_tenderness, leg_swollen, calf_swelling, pitting_edema, collateral_veins, previous_dvt, alternative_diagnosis(-2) |
ClinicalCalc_Wells_PE |
(none) |
clinical_dvt(3), pe_most_likely(3), tachycardia(1.5), immobilization(1.5), previous_vte(1.5), hemoptysis(1), malignancy(1) |
ClinicalCalc_ASCVD_risk |
age(40-79), total_cholesterol, hdl_cholesterol, systolic_bp |
bp_treated, smoker, diabetes, female, race("white"/"black") |
ClinicalCalc_eGFR_CKD_EPI |
creatinine, age |
female |
If a required value is missing, ask the user for it — do not guess. State explicitly which booleans you assumed false.
Step 3 — Compute
tu run ClinicalCalc_CHA2DS2_VASc '{"age":76,"female":true,"hypertension":true,"diabetes":true}'
Every tool returns data.score plus a human-readable data.interpretation and a data.components breakdown (per-factor points). MELD/eGFR/ASCVD also return unit; Child-Pugh returns child_pugh_class; Wells PE returns three_tier and two_tier. Echo the components so the user can audit which factors drove the score.
Step 4 — Interpret (per-score tables)
CHA2DS2-VASc (stroke risk in AF, 0–9)
| Score |
Stroke risk |
Action |
| 0 (men) / 1 (women, sex point only) |
Low |
No anticoagulation |
| 1 (men) |
Intermediate |
Consider anticoagulation |
| >=2 (men) / >=3 (women) |
Elevated |
Oral anticoagulation recommended |
HAS-BLED (major bleeding on anticoagulation, 0–9)
| Score |
Bleeding risk |
Action |
| 0–2 |
Low–moderate |
Anticoagulation reasonable |
| >=3 |
High |
Caution; correct reversible factors (BP, labile INR, antiplatelet/NSAID, alcohol), closer follow-up — NOT an automatic contraindication |
How to weigh CHA2DS2-VASc + HAS-BLED together
A high HAS-BLED does not by itself withhold anticoagulation. If CHA2DS2-VASc meets the threshold, the stroke benefit usually outweighs bleeding risk; HAS-BLED instead flags modifiable risk factors to fix and patients needing closer monitoring. Only a very high, non-modifiable bleeding risk shifts the decision against anticoagulation.
CURB-65 (CAP severity, 0–5)
| Score |
30-day mortality |
Disposition |
| 0–1 |
Low (~1.5–3%) |
Outpatient |
| 2 |
Intermediate (~9%) |
Short-stay / inpatient admission |
| 3–5 |
High (~15–40%) |
Inpatient; assess for ICU at 4–5 |
qSOFA (sepsis screen, 0–3)
| Score |
Meaning |
| 0–1 |
Lower risk — does not rule out sepsis; reassess |
| >=2 |
Higher risk of poor outcome — escalate, full sepsis workup, consider full SOFA / lactate |
| qSOFA is a screen, not a diagnosis; a low score never excludes sepsis. |
|
Child-Pugh (cirrhosis severity, class A/B/C)
| Class |
Score |
1-yr survival (approx) |
Meaning |
| A |
5–6 |
~100% |
Well-compensated |
| B |
7–9 |
~80% |
Significant functional compromise |
| C |
10–15 |
~45% |
Decompensated; high surgical/anesthetic risk |
MELD-Na (90-day mortality / transplant priority, 6–40)
| MELD-Na |
90-day mortality (approx) |
Transplant relevance |
| <=9 |
~2% |
Low priority |
| 10–19 |
~6% |
|
| 20–29 |
~20% |
Rising allocation priority |
| 30–39 |
~50% |
High priority |
| >=40 |
>50% |
Highest priority |
| Pair with Child-Pugh: Child-Pugh class anchors chronic severity / surgical risk; MELD-Na drives short-term mortality and transplant listing. |
|
|
Wells DVT (pretest probability)
| Score |
Probability |
Workup |
| <2 (esp. <=0) |
DVT unlikely |
D-dimer; if negative, DVT excluded |
| >=2 |
DVT likely |
Proceed to compression ultrasound |
Wells PE (pretest probability)
| Two-tier |
Three-tier |
Workup |
| PE unlikely (<=4) |
low (0–1) / moderate (2–6) |
D-dimer; if negative, PE excluded (consider PERC if very low) |
| PE likely (>4) |
high (>6) |
CT pulmonary angiography (D-dimer not sufficient to exclude) |
ASCVD 10-year risk (%)
| Risk % |
Category |
Statin guidance (with shared decision-making) |
| <5% |
Low |
Lifestyle |
| 5–7.4% |
Borderline |
Consider if risk-enhancers present |
| 7.5–19.9% |
Intermediate |
Moderate-intensity statin reasonable |
| >=20% |
High |
High-intensity statin |
eGFR CKD-EPI (mL/min/1.73m^2) → CKD stage
| eGFR |
Stage |
Note |
| >=90 |
G1 |
Normal (CKD only if other markers of damage) |
| 60–89 |
G2 |
Mildly decreased |
| 45–59 |
G3a |
Mild–moderate |
| 30–44 |
G3b |
Moderate–severe |
| 15–29 |
G4 |
Severe — nephrology referral |
| <15 |
G5 |
Kidney failure |
| Use eGFR for renal drug dosing and CKD staging; a single value is an estimate — confirm with a repeat/eGFR trend for staging. |
|
|
Worked example A — Atrial fibrillation, weigh anticoagulation (paired)
76-year-old woman with AF, hypertension, type 2 diabetes; on an NSAID; no prior stroke/bleed, BP controlled, stable INR.
tu run ClinicalCalc_CHA2DS2_VASc '{"age":76,"female":true,"hypertension":true,"diabetes":true}'
# -> score 5: "Elevated risk (5) — oral anticoagulation recommended"
# components: Age>=75 2, Hypertension 1, Diabetes 1, Female 1
tu run ClinicalCalc_HAS_BLED '{"age":76,"hypertension":true,"drugs":true}'
# -> score 3: "High bleeding risk (3) — caution, review reversible factors"
# components: Hypertension_uncontrolled 1, Elderly_>65 1, Drugs_antiplatelet_NSAID 1
Interpretation. CHA2DS2-VASc 5 (>=3 for a woman) → anticoagulation recommended. HAS-BLED 3 is high but driven by modifiable factors: stop the NSAID and control BP and 2 of the 3 points disappear, lowering bleeding risk. The high HAS-BLED does not cancel anticoagulation — it directs you to fix reversible risks and monitor more closely.
Worked example B — Cirrhosis severity and transplant priority (paired)
Cirrhotic patient: bilirubin 3.5 mg/dL, albumin 2.5 g/dL, INR 2.4, moderate ascites, grade 1–2 encephalopathy; creatinine 2.0, sodium 128, not on dialysis.
tu run ClinicalCalc_Child_Pugh '{"bilirubin":3.5,"albumin":2.5,"inr":2.4,"ascites":"moderate","encephalopathy":"grade1-2"}'
# -> score 14, child_pugh_class "C": "Class C (score 14): decompensated disease"
tu run ClinicalCalc_MELD_Na '{"creatinine":2.0,"bilirubin":5.0,"inr":2.0,"sodium":128,"dialysis":false}'
# -> score 31: "MELD-Na 31: very high ... 90-day mortality risk"
Interpretation. Child-Pugh class C (14) = decompensated cirrhosis, very high surgical/anesthetic risk — avoid elective surgery. MELD-Na 31 implies roughly a third-or-higher 90-day mortality and a high transplant-allocation priority. Together they justify urgent hepatology / transplant evaluation. (Note MELD uses bilirubin 5.0 and INR 2.0 from this patient's labs; lower bounds of 1.0 are applied internally.)
Completeness checklist
LIMITATIONS
- Decision-support only. These scores inform, but do not replace, clinical judgment and the full clinical picture. Do not present output as a treatment directive.
- Validated populations. Each score was derived/validated in specific cohorts and may not transfer to children, pregnancy, valvular AF (CHA2DS2-VASc is for non-valvular AF), or other excluded groups.
- ASCVD Pooled Cohort Equations are validated only for ages 40–79 and the White / African-American coefficient sets; they can mis-estimate for other ancestries and are for primary prevention (no prior ASCVD event).
- eGFR CKD-EPI assumes stable kidney function (steady-state creatinine); it is unreliable in acute kidney injury, extremes of muscle mass, or amputees, and a single value does not stage CKD on its own.
- qSOFA / CURB-65 / Wells are screening / pretest-probability tools — a reassuring score does not exclude the diagnosis; combine with clinical gestalt and confirmatory testing.
- MELD-Na / Child-Pugh apply to chronic liver disease; they do not capture acute liver failure or hepatocellular-carcinoma exception points.
- Inputs are taken at face value — garbage in, garbage out. Verify lab units (mg/dL vs mmol/L, BUN vs urea) before entry.
- Not a substitute for institutional protocols, guideline updates, or specialist consultation.